Lithium Exposure and Risk of Major Neurocognitive Disorders: A Systematic Review and Meta-analysis.

IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Journal of Clinical Psychopharmacology Pub Date : 2024-07-01 Epub Date: 2024-05-15 DOI:10.1097/JCP.0000000000001863
Qing Huang, Xue-Qin Ma, Hui-Fang Chen
{"title":"Lithium Exposure and Risk of Major Neurocognitive Disorders: A Systematic Review and Meta-analysis.","authors":"Qing Huang, Xue-Qin Ma, Hui-Fang Chen","doi":"10.1097/JCP.0000000000001863","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Published studies on the association between lithium use and the decreased risk of major neurocognitive disorders (MNCDs) have shown disparities in their conclusions. We aimed to provide updated evidence of this association.</p><p><strong>Methods: </strong>A comprehensive literature search was performed in PubMed, EMBASE, and Cochrane Library from inception until August 31, 2023. All the observational studies evaluating the association between lithium use and MNCD risk were eligible for inclusion. Pooled odds ratios (ORs) and 95% prediction intervals were computed using random-effects models.</p><p><strong>Results: </strong>Eight studies with 377,060 subjects were included in the analysis. In the general population on the association between lithium use versus nonuse and dementia, the OR was 0.94 (95% confidence interval [CI] = 0.77-1.24). Further analysis also demonstrated that lithium use was not associated with an increased risk of Alzheimer's disease (OR = 0.69, 95% CI: 0.31-1.65). When the analysis was restricted to individuals with bipolar disorder to reduce the confounding by clinical indication, lithium exposure was also not associated with a decreased risk of MNCD (OR = 0.9, 95% CI = 0.71-1.15).</p><p><strong>Conclusion: </strong>The results of this systematic review and meta-analysis do not support a significant association between lithium use and the risk of MNCD.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"418-423"},"PeriodicalIF":2.9000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/JCP.0000000000001863","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Published studies on the association between lithium use and the decreased risk of major neurocognitive disorders (MNCDs) have shown disparities in their conclusions. We aimed to provide updated evidence of this association.

Methods: A comprehensive literature search was performed in PubMed, EMBASE, and Cochrane Library from inception until August 31, 2023. All the observational studies evaluating the association between lithium use and MNCD risk were eligible for inclusion. Pooled odds ratios (ORs) and 95% prediction intervals were computed using random-effects models.

Results: Eight studies with 377,060 subjects were included in the analysis. In the general population on the association between lithium use versus nonuse and dementia, the OR was 0.94 (95% confidence interval [CI] = 0.77-1.24). Further analysis also demonstrated that lithium use was not associated with an increased risk of Alzheimer's disease (OR = 0.69, 95% CI: 0.31-1.65). When the analysis was restricted to individuals with bipolar disorder to reduce the confounding by clinical indication, lithium exposure was also not associated with a decreased risk of MNCD (OR = 0.9, 95% CI = 0.71-1.15).

Conclusion: The results of this systematic review and meta-analysis do not support a significant association between lithium use and the risk of MNCD.

锂暴露与主要神经认知障碍的风险:系统回顾与元分析》。
背景:已发表的关于锂的使用与主要神经认知障碍(MNCDs)风险降低之间关系的研究结论存在差异。我们旨在提供这种关联的最新证据:我们在 PubMed、EMBASE 和 Cochrane 图书馆中进行了全面的文献检索,检索时间从开始到 2023 年 8 月 31 日。所有评估锂的使用与 MNCD 风险之间关系的观察性研究均符合纳入条件。采用随机效应模型计算汇总的几率比(ORs)和95%预测区间:共有 8 项研究、377,060 名受试者参与了分析。在普通人群中,使用锂与不使用锂与痴呆之间的相关性的OR值为0.94(95%置信区间[CI] = 0.77-1.24)。进一步的分析还表明,使用锂与阿尔茨海默病风险的增加无关(OR = 0.69,95% CI:0.31-1.65)。当分析仅限于双相情感障碍患者以减少临床适应症的干扰时,锂暴露也与MNCD风险的降低无关(OR = 0.9,95% CI = 0.71-1.15):本系统综述和荟萃分析的结果不支持锂的使用与 MNCD 风险之间存在显著关联。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.00
自引率
3.40%
发文量
231
审稿时长
4-8 weeks
期刊介绍: Journal of Clinical Psychopharmacology, a leading publication in psychopharmacology, offers a wide range of articles reporting on clinical trials and studies, side effects, drug interactions, overdose management, pharmacogenetics, pharmacokinetics, and psychiatric effects of non-psychiatric drugs. The journal keeps clinician-scientists and trainees up-to-date on the latest clinical developments in psychopharmacologic agents, presenting the extensive coverage needed to keep up with every development in this fast-growing field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信